← Leaderboards
Lisa L Wei
Genvec, Inc.
$1,941,075
Attributed
$1,941,075
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $596K · FY2005–09$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$1,941,075 · 6
By mechanism
R43$1,165,291 · 5
R44$775,784 · 1
Top collaborators
No co-investigators on record.
Most similar at Genvec, Inc.
Same institution · by research overlap
- Joseph T Bruder$2,184,286
- Duncan L McVey$3,069,048
- Christopher Davis Reiter$546,430
- C. Richter King$1,667,266
Others in their field
Top investigators on “Angiogenesis Inhibitors”
- Walter John Curran · Thomas Jefferson University$26,641,549
- David Heimbrook · Leidos Biomedical Research, Inc.$24,469,358
- David R Harder · Medical College Of Wisconsin$16,163,720
- Elizabeth Marion Jaffee · Johns Hopkins University$12,679,276
- Garrett M Brodeur · Children'S Hospital Of Philadelphia$12,442,187
- Erwin G Van Meir · University Of Alabama At Birmingham$11,726,130
Research focus
Angiogenesis InhibitorsPreclinical TestingPreventVectorDrug Design /Synthesis /ProductionDiabetic RetinopathyTissue /Cell CultureSmall Business Innovation Research GrantAdenovirus VectorLaboratory MousePre-Clinical ModelResearch Clinical TestingMacular DegenerationAntigensPharmacokineticsNeurotrophic FactorsBiotherapeutic AgentPeptide Chemical SynthesisIn VivoGene ExpressionBaseLaboratoriesImmunityEye Circulation Disorder
Grant awards (7)
Preclinical Testing of an Adenoviral Vector based HSV-2 Vaccine$300,000
R43 · FY2009 · AI · contact PI
Local Therapy-A Novel Approach to Cancer Metastases$295,991
R43 · FY2009 · CA · contact PI
Alternate Adenovector in Eye Gives Longer Expression$329,500
R43 · FY2007 · EY · contact PI
Development of PEDF Protein: An Antiangiogenic Agent$362,389
R44 · FY2005 · EY
Development of PEDF Protein: An Antiangiogenic Agent$413,395
R44 · FY2004 · EY
Alternate Delivery of Potent Antiangiogenic Agent-AdPEDF$139,924
R43 · FY2004 · EY
Protein Production of PEDF-Potent Antiangiogenic Agent$99,876
R43 · FY2003 · EY